Mats Rnngard - Enorama Pharma CEO Member

All Insiders . Sweden . 
Stock . Enorama Pharma AB . Stakeholders . Insider . Mats Rnngard
ERMA Stock  SEK 3.77  0.09  2.33%   

Insider

Mats Rnngard is CEO Member of Enorama Pharma AB
Age 67
Phone46 7 08 72 82 50
Webhttps://www.enorama.se

Enorama Pharma Management Efficiency

The company has return on total asset (ROA) of (0.5277) % which means that it has lost $0.5277 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (32.8791) %, meaning that it generated substantial loss on money invested by shareholders. Enorama Pharma's management efficiency ratios could be used to measure how well Enorama Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Xiaodong WangC Rad AB
44
Ivan AstralagaC Rad AB
N/A
Ulrika PalmMidsona AB
50
Priscilla KazumbaC Rad AB
N/A
Emelie GozziC Rad AB
N/A
Veronika GrozdanovskaNovotek AB
53
Max BokanderMidsona AB
50
Lars LevinC Rad AB
52
Tim ThurnC Rad AB
42
Tobias AntiusNovotek AB
51
Niklas CarlnStille AB
49
Erk SchuchhardtMidsona AB
N/A
Peter sbergMidsona AB
57
Hakan AxelssonC Rad AB
55
Tobias TranebornMidsona AB
48
Antti MPNovotek AB
45
Marjolaine CevozGoyatMidsona AB
N/A
Helena BramstorpNovotek AB
41
Tora MolanderMidsona AB
45
Hanna WilkmanStille AB
56
John AndersonStille AB
48
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden. Enorama Pharma AB (ERMA) is traded on Stockholm Exchange in Sweden and employs 10 people.

Management Performance

Return On Equity-32.88
Return On Asset-0.53

Enorama Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enorama Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-32.88
Return On Asset-0.53
Operating Margin(3.11) %
Current Valuation42.1 M
Shares Outstanding10.69 M
Shares Owned By Insiders78.21 %
Shares Owned By Institutions1.31 %
Price To Book7.67 X
Price To Sales3.82 X
Revenue11.04 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enorama Stock Analysis

When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY